Cambridge, UK - 3rd December 2018
Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 Programme
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
News
Cambridge, UK - 27th November 2018
Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 28th September 2018
Director/PDMR Shareholding
The Company was notified on 28 September 2018 that Kirk…
Cambridge, UK - 28th September 2018
Additional New NXP002 Patent Filing
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 19th September 2018
Result of Annual General Meeting
The Annual General Meeting of Nuformix plc was held on…
Cambridge, UK - 14th September 2018
NXP001 Pre-Clinical Milestone Achieved
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 28th August 2018
Renewal of Loan Notes
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 16th August 2018
2018 Annual Financial Report and Notice of Annual General Meeting
The Company announces that the following documents were posted to…
Cambridge, UK - 15th August 2018
Nuformix PLC – Annual General Meeting – Proxy Form
Nuformix PLC – Annual General Meeting – Proxy Form…
Cambridge, UK - 26th July 2018
Final Results for year ended 31 March 2018
The Board of Nuformix plc, (LSE:NFX) is pleased to announce…
Cambridge, UK - 4th July 2018
CEO Interview – Dr Daniel Gooding : Nuformix
Cambridge, UK - 2nd July 2018
Operational Update
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 26th June 2018
Collaboration with St George Street Capital
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 11th May 2018
Nuformix appoints Dr Chris Blackwell as Non-executive Director
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 24th April 2018
Notification Major Interests Shares
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 2nd March 2018
NFX Update re Broker
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 27th February 2018
TR-1: Standard form for notification of major holdings
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 31st January 2018
Positive Results from NXP002 Pilot Study in Lung and Liver Fibrosis
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 15th December 2017
Cocrystal Agreement for NXP001 with Newsummit Biopharma & £2.5m Payment plus Double Digit Royalty on Sales
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 14th December 2017
NFX Advisory Panel
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 6th December 2017
NFX Broker Appt Warrants
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 1st December 2017
Appointment of Broker
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 19th October 2017
Nuformix signs agreement with Quotient Clinical to commence a pilot bioequivalence study for NXP001
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 19th October 2017
Nuformix signs agreement with Quotient Clinical to commence a pilot bioequivalence study for NXP001
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
Cambridge, UK - 18th October 2017
NFX on Vox Markets
Since shares commenced their first days trading under…
Cambridge, UK - 17th October 2017
‘Takeover’s healthy side effect’ – Completion of Nuformix’s acquisition by Levrett plc in The Times
The news of the completion of Nuformix’s acquisition…
Cambridge, UK - 16th October 2017
Shakespeare Martineau’s Keith Spedding speaks on Levrett plc’s completed acquisition of Nuformix
Having worked on the original IPO of Levrett,…
Cambridge, UK - 16th October 2017
Nuformix CEO, Dan Gooding on Vox Markets – Elevator Pitch
Nuformix CEO, Dan Gooding, provides a first summary…
Cambridge, UK - 16th October 2017
‘£12m take-over for Cambridge firm speeding up drug discovery’ – Nuformix RTO featured in the Cambridge News
The news of the completion of Nuformix’s acquisition…
Cambridge, UK - 16th October 2017
Nuformix CEO, Dan Gooding, interviewed by Vox Markets’ Justin Waite
As Nuformix shares commence their first days…
Cambridge, UK - 16th October 2017
‘Levrett snaps up Cambridge Pharma Company’ – Nuformix RTO featured on Insider Media
The news of the completion of Nuformix’s acquisition…
Cambridge, UK - 16th October 2017
Notice of Admission to Trading on The Official List and to Trading on the London Stock Exchange’s Market for Regulated Securities
Following a Reverse Takeover on the London Stock Exchange’s market…
Cambridge, UK - 16th October 2017
Notice Of Cancellation Of Admission To Trading On The Official List And To Trading On The London Stock Exchange’s Market For Regulated Securities
Following a Reverse Takeover on the London Stock Exchange’s market…
Cambridge, UK - 16th October 2017
Nuformix Investor Summary
Corporate Introduction October 2017 – Click here to download…
Cambridge, UK - 13th October 2017
The Company announces that today the name of the Company has been changed from Levrett plc to Nuformix plc.
Levrett, a Company formed to acquire a target company with…
Cambridge, UK - 13th October 2017
GM Results and Completion of Acquisition of Nuformix Limited
Levrett, a Company formed to acquire a target company with…
Cambridge, UK - 13th October 2017
Interim Results 2017
Levrett, a Company formed to acquire a target company with…
Cambridge, UK - 13th October 2017
Levrett plc announces name change to Nuformix plc.
Levrett plc announces that today the name of the Company…
Cambridge, UK - 13th October 2017
Levrett Announces GM Results and Completion of Acquisition of Nuformix Limited
Levrett, a Company formed to acquire a target company with…
Cambridge, UK - 22nd September 2017
Final Results for the year ended 31 March 2017
Cambridge, UK - 15th September 2017
Proposed Acquisition of Nuformix Limited, Placing of New Ordinary Shares, Approval of a Waiver of obligation under Rule 9 of the City Code on Takeovers and Mergers, Notice of General Meeting and Publishing and Posting of the Prospectus
Levrett plc, a Company formed to acquire a target company…
Cambridge, UK - 15th September 2017
Nuformix announces RTO with Levrett Plc
Nuformix is delighted to announce that Levrett plc, a Company…
Cambridge, UK - 2nd May 2017
Nuformix announces fibrosis programme with Fibrofind
Nuformix has entered into an agreement with Fibrofind to conduct…
Cambridge, UK - 19th January 2017
Nuformix patent for NXP002 is granted in Europe
Nuformix is pleased to announce it has today received the…
Cambridge, UK - 23rd December 2016
Interim Results 2016
Levrett, a Company formed to acquire a target company with…
Cambridge, UK - 6th December 2016
Nuformix patent for NXP002 is granted in the US
Nuformix announces today that the US PTO has granted Nuformix’s…
Cambridge, UK - 30th November 2016
Nuformix extends its partnership with Onyx-IPCA
Following on from Nuformix’s existing cocrystal discovery and development pact…
Cambridge, UK - 23rd November 2016
Nuformix patent for NXP001 is granted in Europe
Nuformix is pleased to announce the grant of its NXP001…
Cambridge, UK - 21st October 2016
Magnus Life Science files first patent following Nuformix Collaboration
Following completion of the first stage of its collaboration with…
Cambridge, UK - 4th October 2016
Nuformix to attend CPhI Europe 2016 in Barcelona
Nuformix will attend CPhI in Barcelona over 5 th –…
Cambridge, UK - 21st September 2016
Levrett PLC New Accounting Ref Date
Levrett announces that the Board has approved a change in…
Cambridge, UK - 16th September 2016
Possible Acquisition and Suspension of Trading
The Directors of Levrett are pleased to inform shareholders that…
Cambridge, UK - 15th September 2016
Vectura cocrystal patent publishes following Nuformix Innovate UK project
Following completion of the Innovate UK funded collaboration between Nuformix…
Cambridge, UK - 1st September 2016
Nuformix to attend opening of Wenzhou Biomedical Innovation Center, China
In partnership with Newsummit Biopharma, a Nuformix strategic development partner,…
Cambridge, UK - 9th August 2016
Nuformix patent for NXP001 is granted in Japan
Nuformix has received official notification from the Japanese PO of…
Cambridge, UK - 29th March 2016
Interim Results 2015
Levrett is pleased to announce its interim results for the…
Cambridge, UK - 24th February 2016
Appointment of Broker and Corporate Update
Levrett is pleased to announce that it has appointed Whitman…
Cambridge, UK - 11th February 2016
Nuformix completes first stage of Magnus Life Science collaboration
Following the commencement of Nuformix’s partnership with Magnus Life Science,…
Cambridge, UK - 17th December 2015
Publication of Prospectus and First Dealings
Levrett is pleased to announce that its entire issued ordinary…
Cambridge, UK - 14th December 2015
Intention to Float
Levrett is pleased to announce its intention to apply for…